June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Relationship of Retinal morphology and Sensitivity in Neovascular Age-related Macular Degeneration (NAMD). Comparision of Ranibizumab versus Aflibercept treatment over 1 year
Author Affiliations & Notes
  • Florian Sulzbacher
    Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Stefan Sacu
    Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Philipp Ken Roberts
    Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Marion Ronit Munk
    Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Maria Elisabeth Kroh
    Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Alexandra Kaider
    Center for Medical Statistics, Informatics, and Intelligent Systems; Section for Clinical Biometrics, Medical University of Vienna, Vienna, Austria
  • Sandra Rezar
    Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Ursula Schmidt-Erfurth
    Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Footnotes
    Commercial Relationships Florian Sulzbacher, None; Stefan Sacu, None; Philipp Roberts, None; Marion Munk, None; Maria Kroh, None; Alexandra Kaider, None; Sandra Rezar, None; Ursula Schmidt-Erfurth, Alcon (C), Bayer Healthcare (C), Boehringer (C), Novartis (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1521. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Florian Sulzbacher, Stefan Sacu, Philipp Ken Roberts, Marion Ronit Munk, Maria Elisabeth Kroh, Alexandra Kaider, Sandra Rezar, Ursula Schmidt-Erfurth, ; Relationship of Retinal morphology and Sensitivity in Neovascular Age-related Macular Degeneration (NAMD). Comparision of Ranibizumab versus Aflibercept treatment over 1 year. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1521.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To compare the OCT-related functional treatment response between Ranibizumab and Aflibercept treatment after 12 month in patients with neovascular age-related macular degeneration (nAMD).

Methods: Fourty four eyes showing untreated nAMD were examined with the Heidelberg Spectralis-OCT (SD-OCT) and the NIDEK MP-1 microperimetry (MP) at baseline, at month 3 and at month 12 receiving a fixed regimen of intravitral ranibizumab (22 eyes) or aflibercept injections (22 eyes).<br /> The fundusphoto (FP) of the MP was exactly matched with the infrared+OCT image of the SD-OCT using imaging processing software.<br /> Each test point of light sensitivity in the FP was transmitted to the corresponding location on SD-OCT and subsequently the microperimetric results were evaluated with respect to the following OCT-findings: neovascular complex (NVC), serous pigment epithelium detachment (sPED), fibrovascular PED (fPED), subretinal fluid (SRF), intraretinal fluid (IRF) and intraretinal cysts (IRC) at baseline and after 1 year.

Results: From baseline to month 12, significant improvements in retinal sensitivity were observed for SRF and sPED, with median [quartile] values of 7dB [3dB, 12dB] / 10.5dB [3dB, 14.5dB] with Ranibizumab and 6dB [0dB, 9dB] / 6dB [5dB, 9dB] with Aflibercept treatment (p<0.0001 for both agents). From baseline to month 12 no significant change in median retinal sensitivity was observed for NVC, IRF, fPED, IRC neither with Ranibizumab treatment with median [quartile] values of 0.5dB [0dB, 5dB], 1dB [-2.5dB, 6dB], 0dB [-3dB, 6dB], -4dB [-8dB, -1dB] nor with Aflibercept treatment with 0dB [0dB, 0dB], 0dB [-2dB, 5dB], 3dB [-3dB, 8dB], 0dB [-5dB, 2dB], (p>0.1 for both agents).

Conclusions: After 1 year Ranibizumab and Aflibercept showed equal significant benefit for SRF and sPED whereas for NVC, fPED, IRF and IRC no significant benefit was registered for both agents.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×